Exact Sciences Highlights the Impact of Precision Oncology Portfolio on Breast Cancer Treatment with 10 New Data Presentations at SABCS® 2022

(marketscreener.com) New independent clinical evidence from the pivotal TAILORx and RxPONDER trials support the role of the Oncotype DX Breast Recurrence Score® test, the only genomic test to predict chemotherapy benefit in early-stage breast cancer patients 1,2,3,4Initial validation study of a new test to predict radiotherapy benefit will be highlighted in the...https://www.marketscreener.com/quote/stock/EXACT-SCIENCES-CORPORATIO-9232/news/Exact-Sciences-Highlights-the-Impact-of-Precision-Oncology-Portfolio-on-Breast-Cancer-Treatment-with-42489660/?utm_medium=RSS&utm_content=20221206